doranidazole has been researched along with carboplatin in 1 studies
| Studies (doranidazole) | Trials (doranidazole) | Recent Studies (post-2010) (doranidazole) | Studies (carboplatin) | Trials (carboplatin) | Recent Studies (post-2010) (carboplatin) |
|---|---|---|---|---|---|
| 30 | 4 | 10 | 12,895 | 4,001 | 5,244 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ariyoshi, Y; Fukuoka, M; Fuwa, N; Hida, T; Hirokawa, K; Katakami, N; Kawahara, M; Nakagawa, K; Negoro, S; Nishimura, Y; Segawa, Y; Takeda, K; Tanaka, M; Tsujino, K; Yamamoto, N | 1 |
1 trial(s) available for doranidazole and carboplatin
| Article | Year |
|---|---|
Phase I/II trial of sequential chemoradiotherapy using a novel hypoxic cell radiosensitizer, doranidazole (PR-350), in patients with locally advanced non-small-cell lung Cancer (WJTOG-0002).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiation Pneumonitis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Rate | 2007 |